Skip to main content
. 2014 Oct 28;20(40):14821–14830. doi: 10.3748/wjg.v20.i40.14821

Figure 1.

Figure 1

Effects of glucagon-like peptide-1 receptor agonist on non-alcoholic fatty liver disease and inflammation. PPAR-α: Peroxisome proliferator-activated receptor; IHL: intrahepatic lipids; AMPK: AMP-activated protein kinase; CRP: C reactive protein; AGEs: Advanced glycation and end products; JNK: c-Jun NH2-terminal kinase; GLP-1RA: Glucagon-like peptide-1 receptor agonist; NAFLD: Non-alcoholic fatty liver disease.